Aber nur eine einzige humane klinische Studie erfllte die Einschlusskriterien fr die Review-Analyse
Digestive Symptoms In a 2-week study in 14 people with histamine intolerance and symptoms that included abdominal pain, bloating, or diarrhea, 93% of participants reported a resolution of at least one digestive symptom after taking 4.2 mg of DAO twice daily ( Migraine Attacks and Headaches A 1-month study in 100 people with previously diagnosed DAO deficiency observed that participants who supplemented daily with DAO experienced a 23% reduction in the duration of migraine attacks, compared to the placebo group ( Skin Rash A 30-day study in 20 people with chronic spontaneous urticaria (skin rash) and DAO deficiency noted that participants who received the supplement twice daily experienced significant relief in symptoms and required less antihistamine medication ( Although these studies suggest that supplementing with DAO may eliminate or improve symptoms of deficiency, theres no guarantee that its effective for everyone
Disclosures: Luz Esther Ramos Ballesteros: Nothing to Disclose, Bertrand Lebouch: Merck Canada: Speaking and Teaching, Gilead: Speaking and Teaching, ViiV healthcare: Consultant, Gilead: ASAP study managed by RI-MUHC, Merck: I score study and core set study managed by RI-MUHC, ViiV: PIVHOT progra mfro patients managed by RI-MUHC, Jean-Pierre Routy: Nothing to Disclose, Marina Klein: Nothing to Disclose, Jason Szabo: Nothing to Disclose, Joseph Cox: Nothing to Disclose, Julian Falutz: EMD Sermon: Advisor, ViiV: Speaking and Teaching, Merck: Speaking and Teaching, Louis-Patrick Haraoui: Nothing to Disclose, Cecilia Costiniuk: Nothing to Disclose, Alexandra De Pokomandy: Nothing to Disclose, Felice Cinque: Nothing to Disclose, Tom Pembroke: Nothing to Disclose, Marco Constante: Nothing to Disclose, Manuela Santos: Nothing to Disclose, Giada Sebastiani: Novo Nordisk: Consultant, Abbvie: Speaking and Teaching, Merck: Consultant, Gilead: Speaking and Teaching, Theratechnologies Inc.: Grant/Research Support 1178 NEW STEATOTIC LIVER DISEASE DIAGNOSTIC PERFORMANCE IN A CHILEAN AGRICULTURAL POPULATION COHORT Maria Spencer Sandino 1 Laura Andrea Huidobro 2 Franco Godoy 1 Danilo Alvares 3 Juan Pablo Arab 4 Daniel Cabrera 5 Marco Arrese 1 Francisco Barrera 1 Catterina Ferreccio 1 , 1 Pontificia Universidad Catlica de Chile, 2 Universidad Catlica del Maule, 3 University of Cambridge, 4 Western University and London Health Sciences Centre, 5 Universidad de los Andes Background: Non- alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease globally, with rising rates, particularly in Latin America, due to the increasing tide of obesity and type 2 diabetes
Also supports the formation of fatty acids and glucose which is used to fuel the body
The Natural Cleanup: Once the fat cells are broken down, their liquid contents (triglycerides) are released into the interstitial fluid
